drugset / Trial / NCT03767738

Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe

NCT03767738

Phase 4 Completed 65 enrolled Regeneron Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection. The secondary objective of the study is to assess ocular safety in the study eye.

Timeline

Start
2018-12-19
Primary completion
2020-08-19
Completion
2020-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic Intravitreal